Community pharmacists hail FG ban on importation of

Nigeria's Federal Government has updated its schedule of prohibited trade items to include pharmaceuticals already manufactured domestically—a landmark policy shift that pharmacists say will reshape the $5+ billion Nigerian pharmaceutical sector and address chronic foreign exchange pressure.

The Association of Community Pharmacists of Nigeria (ACPN) formally endorsed the ban on Monday, calling it a "strategic move" to strengthen local manufacturing capacity, conserve scarce naira reserves, and fortify national health security. This import restriction targets finished drugs where domestic alternatives exist, effectively creating a protected market for Nigerian manufacturers while discouraging the foreign currency drain caused by duplicate imports.

## Why is Nigeria banning pharmaceutical imports now?

Nigeria loses an estimated $2–3 billion annually to pharmaceutical imports, representing 15–20% of total merchandise imports by value. The naira has depreciated 60% since 2021, making import bills unsustainable. By restricting imports of drugs already produced locally, the government aims to redirect spending toward domestic factories, which employ over 150,000 workers and operate at 30–40% capacity utilization. Local manufacturers including May & Baker, Emzor, Juhel, and GlaxoSmithKline Nigeria have long lobbied for tariff protection and import restrictions—a request that has now materialized at policy level.

## What drugs are affected by the new schedule?

The updated prohibited items list targets common, high-volume drugs: antimalarials (artemisinin-based combinations), antibiotics (amoxicillin, ampicillin), analgesics (paracetamol, ibuprofen), and anti-hypertensives already made by registered Nigerian manufacturers. Notably, the ban excludes specialized oncology drugs, rare biologics, and APIs (active pharmaceutical ingredients) not yet produced locally—maintaining access to medicines Nigerians cannot source domestically. Industry sources suggest the list could expand to 200+ SKUs within 18 months, potentially covering 40% of current import volume.

## Market implications: opportunity and risk

**For local manufacturers:** The policy creates immediate upside. Companies like Emzor and May & Baker can increase production volumes without import competition, improve capacity utilization, and reinvest in R&D. However, they face pressure to maintain price discipline—the government has signaled it will monitor for profiteering, and ACPN has pledged to advocate for "affordable pricing."

**For consumers and healthcare:** Domestically manufactured drugs are typically 20–30% cheaper than imports due to lower logistics and forex costs. The ban should ease retail prices for common medications. However, transition friction during the first 6–12 months—supply gaps, initial price volatility, and production bottlenecks—is likely. The government will need to enforce the ban credibly to prevent smuggling of cheaper imports through unofficial channels.

**For investors:** This is a structural bull case for Nigerian pharma equities. Publicly listed firms (PHARMA on the Nigerian Exchange has underperformed for three years) should see margin expansion and volume growth. Private equity interest in local manufacturers is already rising. However, execution risk is real: Nigerian factories must scale quality and output without supply chain disruptions.

## What's next?

Implementation begins within 30 days of gazette publication. The National Agency for Food and Drug Administration and Control (NAFDAC) will enforce compliance at ports. Expect pressure from importers and foreign pharmaceutical companies to carve exemptions—a test of government commitment to the policy.

---

#